Palisade Bio (Palisade Bio) EBIT per Share : $-24.64 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio EBIT per Share?

Palisade Bio's EBIT per Share for the three months ended in Mar. 2024 was $-4.59. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-24.64.

During the past 3 years, the average EBIT per Share Growth Rate was 77.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Palisade Bio's EBIT per Share or its related term are showing as below:

PALI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 77 Med: 77 Max: 77
Current: 77

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Palisade Bio was 77.00% per year. The lowest was 77.00% per year. And the median was 77.00% per year.

PALI's 3-Year EBIT Growth Rate is ranked better than
98.46% of 1299 companies
in the Biotechnology industry
Industry Median: 3.4 vs PALI: 77.00

Palisade Bio's EBIT for the three months ended in Mar. 2024 was $-3.53 Mil.

Palisade Bio EBIT per Share Historical Data

The historical data trend for Palisade Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio EBIT per Share Chart

Palisade Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-2,521.75

-2,018.17

-241.48

-26.94

Palisade Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial											-8.13	-7.92	-7.32	-4.80	-4.59

Palisade Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Palisade Bio's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-12.285	/	0.456
=	-26.94

Palisade Bio's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.526	/	0.768
=	-4.59

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.64

Palisade Bio (NAS:PALI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Palisade Bio EBIT per Share Related Terms

Thank you for viewing the detailed overview of Palisade Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Palisade Bio (Palisade Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

7NS:Germany

Address

5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008

Website

https://www.palisadebio.com

Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Executives

Donald Allen Williams	director	C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley	officer: Chief Financial Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones	officer: Chief Medical Officer	70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae	officer: Chief Operating Officer	675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam	director, officer: Chief Executive Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson	officer: Chief Medical Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center	10 percent owner	2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal	director	2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei	director	P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter	director, officer: Executive Chairman	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma	director	14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142